Clinical Outcomes from Androgen Signaling–directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302 Academic Article uri icon

Overview

MeSH Major

  • Abiraterone Acetate
  • Antineoplastic Agents, Hormonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Density Conservation Agents
  • Bone Neoplasms
  • Prostatic Neoplasms, Castration-Resistant
  • Steroid Synthesis Inhibitors

abstract

  • This analysis showed limited clinical benefit for subsequent abiraterone acetate plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer following initial treatment with abiraterone acetate plus prednisone. This analysis does not support prioritization of subsequent abiraterone acetate plus prednisone or enzalutamide following initial therapy with abiraterone acetate plus prednisone.

publication date

  • July 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2017.03.007

PubMed ID

  • 28314611

Additional Document Info

start page

  • 10

end page

  • 13

volume

  • 72

number

  • 1